WACKER Q2 2026 results — PACE savings and pension effect boost earnings

Key highlights
  • Group sales in Q2 2026 were €1.52 billion, up 7% year‑on‑year.
  • EBITDA was €211 million, including €36.7 million pension‑related non‑operating income; operational EBITDA was €175 million.
  • Net income for the quarter was €350 million and net cash flow was €243 million, supported by €185.4 million from the sale of Siltronic shares.
  • Full‑year sales growth forecast cut to mid‑single‑digit; EBITDA guidance raised to €625–750 million and net financial debt now expected at about €500 million.

Key figures

Group sales in Q2 2026 were €1.52 billion, 7% above Q2 2025 and 8% up on Q1 2026. Reported EBITDA was €211 million, yielding a 13.9% margin; EBIT was €96 million and net income €350 million. Earnings per share amounted to €6.86.

PACE and special effects

EBITDA benefited from savings under the PACE cost‑savings and efficiency program launched in October 2025 and included €36.7 million of non‑operating income from a revaluation of pension provisions after the introduction of a lump‑sum option in Germany. WACKER reports operational EBITDA of €175 million excluding that pension effect.

Regional and divisional performance

About 83% of sales were generated outside Germany. All divisions posted higher sales year‑on‑year: Silicones €757m, Polymers €406m, Biosolutions €99m and Polysilicon €226m. EBITDA rose in Silicones, Polymers and Biosolutions but fell in Polysilicon due to weaker solar‑grade demand and higher energy costs.

Capital, cash, workforce and guidance

Capex in Q2 was €59 million. Net cash flow was €243 million, aided by €185.4 million from Siltronic share proceeds; €243 million of Siltronic‑related effects are reflected in net income. Headcount stood at 16,084. WACKER trimmed full‑year sales growth to mid‑single‑digit, now expects EBITDA of €625–750 million, capex about €300 million, and net financial debt around €500 million.

Source: WACKER

chemXplore Weekly

The week’s project milestones and project news from the chemical industry, free every Wednesday.

Free. One email a week. Unsubscribe any time.

Related articles

14 April 2026
WACKER and Amyris partner on bio-based personal-care ingredients

Develop bio-based functional ingredients for cosmetics; expand silicone range with renewable raw materials; test novel molecules and production integration.

26 May 2026
WACKER sells 2.1 million Siltronic shares, raising €188 million

Placed at €89.35 each (7% of capital), reducing stake to ~24%; private accelerated bookbuild to qualified/institutional investors; proceeds to strengthen finances and fund growth.

26 May 2026
WACKER to reduce stake in Siltronic

Announces a corporate transaction and warns that access restrictions in the preceding filter must be acknowledged before the information is displayed.

17 September 2026
WACKER REFOCUS: pursue GDP+ growth, 15% EBITDA margin and ROCE >10%

Selective growth in electronics, healthcare and mobility; €300–€400m annual investment; PACE to save >€300m/year from 2028; Net Zero by 2045.

31 July 2025
WACKER Q2 Earnings Meet Expectations

Sales and EBITDA fell due to weak demand and trade uncertainties. Net income was negative. Full-year outlook revised down. Focus on growth, cash, and cost management.